Pharma’s next big obesity win will be a challenge
Two studies this week found patients who used Novo Nordisk’s Wegovy anti-obesity injection sustained weight loss for up to four years and showed a lower risk of heart disease.
How weight loss drugs, which also include Eli Lilly’s Zepbound jab, might relieve public health burdens is prompting Big Pharma and investors to search for the next breakthrough. The most valuable prize will be the first pill that can deliver similar results to Wegovy and Zepbound. That may be possible — but finding a pill that can be easily manufactured is a bigger challenge.
Companies such as AstraZeneca argue oral treatments, which are generally easier and cheaper to produce, could reach more people and are preferred by patients.
Veja mais

